Healthcare company Baxter International (NYSE: BAX) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 2.9% year on year to $2.70 billion. Its non-GAAP profit of $0.36 per share was 15.9% above analysts’ consensus estimates.

Is now the time to buy BAX? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Baxter’s first quarter results received a positive market reaction, reflecting management’s progress on its turnaround strategy despite ongoing operational and margin pressures. Key drivers cited included robust growth in advanced surgery products, steady order volumes in care and connectivity solutions, and initial benefits from efforts to stabilize supply chains and address manufacturing backlogs. CEO Andrew Hider acknowledged the quarter’s challenging comparisons to last year, noting, “We are not satisfied with where our performance stands today, but we have a roadmap in place to improve results and drive shareholder value.” While challenges persist in the pharmaceutical and infusion pump segments, proactive cost controls and targeted innovation initiatives supported the company’s first-quarter performance.

Looking forward, Baxter’s reiterated full-year outlook is grounded in anticipated second-half improvements, driven by new product launches and expected resolution of supply and cost headwinds. Management is focused on executing its continuous improvement program, Baxter GPS, to drive efficiency and accountability across business units. CFO Anita Zielinski emphasized, “We expect improvement in organic sales growth, operating margin and adjusted earnings in the back half of the year,” pointing to seasonality, cost structure actions, and product innovation as central to the company’s guidance. The company continues to monitor external pressures, including tariffs and inflation, while banking on its growing pipeline of AI-enabled products and operational discipline for future growth.

Key Insights from Management’s Remarks

Management attributed quarterly revenue performance to advanced surgery growth, progress on supply chain recovery, and targeted innovation, while margin pressures stemmed from elevated manufacturing costs and tariffs.

• Advanced Surgery segment growth: The advanced surgery business sustained double-digit growth this quarter, driven by strong demand for hemostats and sealants and steady global procedure volumes. Management sees this segment as a core area of ongoing momentum.
• Manufacturing and supply chain progress: Baxter made significant progress clearing back orders in pharmaceutical manufacturing, improving throughput and working capital efficiency. However, lingering supply constraints, especially with contract manufacturers, continued to impact injectables and anesthesia product sales.
• Infusion pump portfolio challenges: Infusion Therapies and Technologies faced lower sales due to a shipment and installation hold on the Novum large volume pump (LVP). Management is supporting customers with mitigation measures and working to finalize hardware and software corrections, but has factored the risk of returns and ongoing disruption into full-year guidance.
• Tariffs and inflationary headwinds: Elevated manufacturing costs and new tariffs weighed on gross and operating margins. Management stated that proactive supply chain management and dual sourcing efforts are underway to limit the impact, but inflation and oil price volatility remain persistent headwinds.
• Deployment of continuous improvement program (GPS): The Baxter Growth and Performance System (GPS) has now launched over 230 process improvement events, embedding a culture of accountability and data-driven decision making. Early gains in cash flow and service reliability are being seen, but management cautions that this is an ongoing transformation rather than a short-term fix.

Drivers of Future Performance

Management expects second-half improvement based on product launches, operational efficiencies, and normalization of supply constraints, while external headwinds and ongoing transformation remain key variables.

• Product innovation and launches: New offerings, such as the Connex 360 platform and the Dynamo smart hospital stretcher, are anticipated to drive incremental growth, particularly in the Healthcare Systems & Technology segment. Management highlights AI integration and automation as differentiators, with several more launches slated for the second half of the year.
• Margin recovery initiatives: The company expects operating margins to improve in the back half, primarily from higher volumes, the realization of cost structure actions, and the completion of elevated inventory absorption costs. Management estimates that half of the anticipated margin expansion will come from seasonal volume leverage, while targeted cost reductions and normalization of input costs will provide additional lift.
• Mitigation of external risks: While inflation, tariffs, and oil price volatility continue to present challenges, management’s proactive dual sourcing and supply chain adjustments aim to limit their impact. However, any material changes in the macroeconomic or regulatory environment could affect execution and performance relative to current guidance.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will focus on (1) the pace and commercial impact of new product launches in Connected Care and Advanced Surgery, (2) evidence of margin recovery from cost structure initiatives and operational improvements, and (3) resolution of supply chain bottlenecks, particularly in the injectables and infusion pump segments. Progress on these fronts, along with updates on the permanent CFO search and further adoption of GPS initiatives, will be key milestones to watch.

Baxter currently trades at $17.62, up from $16.90 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.